Shareholders' Equity (Details) - Schedule of activity in warrants |
3 Months Ended |
|---|---|
|
Mar. 31, 2022
$ / shares
shares
| |
| Schedule of activity in warrants [Abstract] | |
| Warrants, Beginning Balance (in Shares) | shares | 7,990,271 |
| Weighted Average Remaining Term (Years), Outstanding | 2 years 7 months 17 days |
| Weighted Average Exercise Price, Outstanding | $ 4.82 |
| Average Intrinsic Value, Outstanding | $ 0.14 |
| Warrants, Issued (in Shares) | shares | 6,042,888 |
| Weighted Average Exercise Price, Issued | $ 1.74 |
| Warrants, Ending Balance (in Shares) | shares | 14,033,159 |
| Weighted Average Remaining Term (Years), Outstanding | 3 years 25 days |
| Weighted Average Exercise Price, Outstanding | $ 3.49 |
| Average Intrinsic Value, Outstanding | $ 0.27 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Outstanding weighted average remaining contractual term. No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining term years, outstanding. No definition available.
|
| X | ||||||||||
- Definition Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|